Techniques in Regional Anesthesia & Pain Management
Volume 14, Issue 1 , Pages 19-24 , January 2010

Decision-making in the cancer pain setting: Beyond the WHO ladder

  • Tristan Picot, MD

      Affiliations

    • Anderson Cancer Center, University of Texas M. D., Houston, Texas
    • ,
  • Basem Hamid, MD

      Affiliations

    • Comprehensive Pain Center of Texas, Houston, Texas
    • Corresponding Author InformationAddress reprint requests and correspondence: Basem Hamid, MD, Comprehensive Pain Center of Texas, 11920 Astoria Blvd, Suite 130, Houston, TX 77089

References 

  1. Aragon-Poce F, Martinez-Fernandez E, Marquez-Espinos C, et al. History of opium. Int Congr Ser. 2002;1242:19–21
  2. Goodrich J. History of spine surgery in the ancient and medieval worlds. Neurosurg Focus. 2004;16:E2
  3. Bonica J. Importance of the problem. In:  Bonica J,  Ventafridda V editor. Proceedings of the First International Congress on Cancer Pain: Advances in Pain Research and Therapy, vol 2. New York: Raven; 1979;p. 1–12
  4. Meldrum M. The ladder and the clock: Cancer pain and public policy at the end of the twentieth century. J Pain Symptom Manage. 2005;29:41–54
  5. Stjernswärd J, Joranson D. Opioid availability and cancer pain: An unnecessary tragedy. Support Care Cancer. 1995;3:157–158
  6. Ahmedzai S. New approaches to pain control in patients with cancer. Eur J Cancer. 1997;33(suppl 6):S8–S14
  7. Benyamin R, Trescot A, Datta S, et al. Opioid complications and side effects. Pain Physician. 2008;11:S105–S120
  8. Pacifici R, Patrini G, Venier I, et al. Effect of morphine and methadone acute treatment on immunological activity in mice: Pharmacokinetic and pharmacodynamic correlates. J Pharmacol Exp Ther. 1994;269:1112–1116
  9. Villars P, Dodd M, West C, et al. Difference in the prevalence and severity of side effects based on type of analgesic prescription in patients with chronic cancer pain. J Pain Symptom Manage. 2007;33:67–77
  10. Gupta K, Kshirsagar S, Chang L, et al. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res. 2002;62:4491–4498
  11. Poonawala T, Levay-Young B, Hebbel R, et al. Opioids heal ischemic wounds in the rat. Wound Repair Regen. 2005;13:165–174
  12. Zagon I, McLaughlin P. Naltrexone modulates tumor response in mice with neuroblastoma. Science. 1983;221:671–673
  13. Farooqui M, Li Y, Rogers T, et al. COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumor growth, metastasis and mortality, without compromising analgesia. Br J Cancer. 2007;97:1523–1531
  14. Aloisi A, Pari G, Ceccarelli I, et al. Gender-related effects of chronic non-malignant pain and opioid therapy on plasma levels of macrophage inhibitory factor (MIF). Int J Dev Neurosci. 2005;23:621–626
  15. Daniell H, Lentz R, Mazer N. Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency. J Pain. 2006;7:200–210
  16. Daniell H. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain. 2008;9:28–36
  17. Kaergaard A, Hansen A, Rasmussen K, et al. Association between plasma testosterone and work-related neck and shoulder disorders among female workers. Scand J Work Environ Health. 2000;26:292–298
  18. English K, Steeds R, Jones T, et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation. 2000;102:1906–1911
  19. Pirnik Z, Schwendt M, Jezova D. Single dose of morphine influences plasma corticosterone and gene expression of main NMDA receptor subunit in the adrenal gland but not in the hippocampus. Endocr Regul. 2001;35:187–193
  20. Chu L, Angst M, Clark D. Opioid induced hyperalgesia in humans: Molecular mechanisms and clinical considerations. Clin J Pain. 2008;24:479–496
  21. King T, Ossipov M, Vanderah T, et al. Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance?. Neuro Signals. 2005;14:194–205
  22. Huang C, Ross P, Wasnich R. Vertebral fracture and other predictors of physical impairment and health care utilization. Arch Intern Med. 1996;156:2469–2475
  23. Lindsay R, Silverman S, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001;285:320–323
  24. Charnley J. The reaction of bone to self-curing acrylic cement: A long-term histological study in man. J Bone Joint Surg Br. 1970;52:340–353
  25. Liberman I, Dudeney S, Reinhardt M, et al. Initial outcome and efficacy of “kyphoplasty” in the treatment of painful osteoporotic vertebral compression fractures. Spine. 2001;26:1631–1638
  26. Burton A, Hamid B. Kyphoplasty and vertebroplasty. Curr Pain Headache Rep. 2008;12:22–27
  27. McKiernan F, Faciszewski T, JensenR . Quality of life following vertebroplasty. J Bone Joint Surg Am. 2004;86-A:2600–2606
  28. McGraw J, Cardella J, Barr J, et al. Society of International Radiology quality improvement guidelines for percutaneous vertebroplasty. J Vasc Interv Radiol. 2003;14:827–831
  29. Phillips F, Todd Wetzel F, Lieberman I, et al. An in vivo comparison of the potential for extravertebral cement leak after vertebroplasty and kyphoplasty. Spine. 2002;27:2173–2178
  30. Walker D, Mummaneni P, Rodts G. Infected vertebroplasty (Report of two cases and review of the literature). Neurosurg Focus. 2004;17:E6
  31. O'Brien J, Sims J, Evans A. Vertebroplasty in patients with severe vertebral compression fractures: A technical report. AJNR Am J Neuroradiol. 2000;21:1555–1558
  32. Peh W, Giluda L, Peck D. Percutaneous vertebroplasty for severe osteoporotic vertebral body compression fractures. Radiology. 2002;223:121–126
  33. Burton A, Reddy S, Shah H, et al. Percutaneous vertebroplasty—A technique to treat refractory spinal pain in the setting of advanced metastatic cancer: A case series. J Pain Symptom Manage. 2005;30:87–95
  34. Jensen M, Evans A, Mathis J, et al. Percutaneous polymethylmethacrylate vertebroplasty in the treatment of osteoporotic vertebral body compression fractures: Technical aspects. AJNR Am J Neuroradiol. 1997;18:1897–1904
  35. American Cancer Society. Cancer Facts and Figures 2004. Atlanta, GA: American Cancer Society; 2004;
  36. Ghaneh P, Costello E, Neoptolemos J. Biology and management of pancreatic cancer. Gut. 2007;56:1134–1152
  37. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet. 2004;363:1049–1057
  38. Brescia F, Portenoy R, Ryan M, et al. Pain, opioid use, and survival in hospitalized patients with advanced cancer. J Clin Oncol. 1992;10:149–155
  39. Cruciani R, Jain S. Pancreatic pain: A mini review. Pancreatology. 2008;8:230–235
  40. Ward E, Rorie D, Nauss L, et al. The celiac ganglia in man: Normal anatomic variations. Anesth Analg. 1979;58:461–465
  41. Eisenberg E, Carr D, Chalmers T. Neurolytic celiac plexus block for treatment of cancer pain: A meta-analysis. Anesth Analg. 1995;80:290–295
  42. Wong G, Schroeder D, Carns P, et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: A randomized controlled trial. JAMA. 2004;291:1092–1099
  43. Yan B, Myers R. Neurolytic celiac plexus block for pain control in unresectable pancreatic cancer. Am J Gastroenterol. 2007;102:430–438

PII: S1084-208X(09)00116-5

doi: 10.1053/j.trap.2009.12.003

Techniques in Regional Anesthesia & Pain Management
Volume 14, Issue 1 , Pages 19-24 , January 2010

Article Tools